CytRx Corporation's (NASDAQ:CYTR) majority-owned subsidiary, RXi Pharmaceuticals Corporation (RXi), today announced the grant of an Australian patent issued to the University of Massachusetts Medical School covering in vivo production of small interfering RNA (siRNA) that mediate gene silencing.

CytRx Corporation (NASDAQ:CYTR) today announced that the RNA interference (RNAi) delivery technology exclusively licensed to its majority-owned subsidiary, RXi Pharmaceuticals Corporation (RXi), has been published in the April 2007 issue of peer-reviewed scientific journal ACS Chemical Biology.

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported financial results for the year ended December 31, 2006.

CytRx Corporation (NASDAQ:CYTR) today announced th

CytRx Corporation (NASDAQ:CYTR) today announced that it has contributed its RNA interference (RNAi) assets to RXi Pharmaceuticals Corporation (RXi), which is co-owned by CytRx and several world leaders in RNAi technology.